Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
about
Future therapeutic targets in rheumatoid arthritis?Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis.Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.Filgotinib for the treatment of rheumatoid arthritis.Efficacy of baricitinib in the treatment of rheumatoid arthritis.Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study.Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential.Baricitinib: First Global Approval.Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatmentSafety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.Treatment with Biologicals in Rheumatoid Arthritis: An Overview.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.A review of sarilumab for the treatment of rheumatoid arthritis.Investigational drugs in systemic vasculitis.Regulation of T-Cell Signaling by Post-Translational Modifications in Autoimmune Disease.A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System.Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic ReviewIncreased Binding of Specificity Protein 1 to the Promoter in B Cells Results in Enhanced B Cell Responses in Rheumatoid ArthritisStructural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
P2860
Q33841419-DE0C0257-FAEB-4AB1-A3B1-4CF3A8B473D5Q37587409-2747512D-3DA0-43A9-8D16-BAED767D109FQ38372369-E123B13C-CAC1-4FF0-8E66-F0B97D9A0213Q38609755-60F2C110-2B82-4404-AF6F-A58B9BBEBF99Q38652849-761F8AFE-10FB-43D2-B4EB-D83AC3DE7D8DQ38821079-1F552034-C5EE-482A-9C5C-8AD184FDB78DQ38932097-B1A5A3F0-7B02-43FB-8B31-89EE001E9D96Q39177156-41F8BBA0-A5B5-461F-A317-598007299CF0Q41704162-D98423D1-A36F-4BDC-9FD7-5A70142BA9D0Q42701803-DC02ACF9-D45F-44BB-A332-AC5A2281FFCDQ47132835-E2D9AEBB-8B42-432B-AC4E-39FCBD717E1BQ47439880-6A4F68EC-9D8E-41C6-9448-024DBC01500BQ47602038-8791092D-1421-4B6D-886C-93619FDD83CCQ48556502-4C36E425-1532-4E7C-AE7C-4EC3B33BC8ACQ49792187-2425F4A4-D3BA-4EA7-BE37-33321C3FEA95Q50086851-70C24E19-DC8D-4866-B88D-92A1C5FDA917Q51834131-C37841D2-CA50-4BE7-8FA1-6EC9FDFE07ABQ52689527-2D0BB1AD-9864-448C-81DF-8C317317CD66Q53791793-92DC5316-E526-4F7E-8BD5-DF863FC25B36Q54977224-08C5B2A1-CD5F-4B9D-8101-A6E7EE23FA79Q54998113-EE5D7797-38E9-4230-AD5F-C4BD717618A4Q55071760-BD59B17D-A736-4E56-B121-E47609A3488DQ55619613-E3A84B58-7C80-4AB8-BC1F-7944C0390C81Q58732393-18570763-315F-4D86-96AC-74A193142FA2Q58762971-F8A84084-4AFA-429D-A636-96C3B157D40FQ58800533-49ECABA2-EEAC-4C63-99DB-F038C7AA3384
P2860
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Baricitinib, Methotrexate, or ...... Antirheumatic Drug Treatment.
@en
Baricitinib, Methotrexate, or ...... Antirheumatic Drug Treatment.
@nl
type
label
Baricitinib, Methotrexate, or ...... Antirheumatic Drug Treatment.
@en
Baricitinib, Methotrexate, or ...... Antirheumatic Drug Treatment.
@nl
prefLabel
Baricitinib, Methotrexate, or ...... Antirheumatic Drug Treatment.
@en
Baricitinib, Methotrexate, or ...... Antirheumatic Drug Treatment.
@nl
P2093
P2860
P50
P356
P1476
Baricitinib, Methotrexate, or ...... Antirheumatic Drug Treatment.
@en
P2093
Alberto Spindler
Christina Dickson
Cristiano A F Zerbini
Douglas Schlichting
Marina Stanislav
Michael Schiff
Roy Fleischmann
Scott Beattie
Sirel Gurbuz
Stephanie de Bono
P2860
P304
P356
10.1002/ART.39953
P577
2016-10-09T00:00:00Z